In mild to moderate COVID-19, VV116 safely reduced time to sustained clinical symptom resolution.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 38437701.
- Also identified by DOI 10.7326/J24-0006.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Fan X, Dai X, Ling Y, et al. <b>Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study.</b> Lancet Infect Dis. 2024;24:129-139. 38006892.
Medical subject headings
- Adenosine
- COVID-19